Lung cancer vaccines and gene therapy

被引:28
作者
Hege, KM
Carbone, DP
机构
[1] Cell Genesys Inc, San Francisco, CA 94080 USA
[2] Vanderbilt Univ, Ingram Canc Ctr, Nashville, TN 37232 USA
关键词
tumor vaccine; gene therapy; lung cancer; GVAX (R); MUC1; BEC2; Mage-3; p53; H5V-tk; ONYX-015;
D O I
10.1016/S0169-5002(03)00153-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A number of cancer vaccine and gene therapy approaches are being evaluated in patients with lung cancer. Cancer vaccine strategies include GM-CSF gene-modified cancer cells, liposomal MUC1 peptide, anti-idiotype antibody targeting GD3, Mage-3 peptide, and mutant p53 pulsed dendritic cells among others. Preliminary human trials have demonstrated immune responses as well as tumor regression in late stage disease. The largest human gene therapy experience in lung cancer is with intratumoral gene replacement therapy, predominantly with p53, but such approaches are limited to locoregional disease control. Earlier stage gene therapy programs targeting the immune system or tumor vasculature hold promise as systemic therapies for treatment of advanced, disseminated disease. (C) 2003 Elsevier Science Ireland Ltd and American Society of Clinical Onocology. Published by Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:S103 / S113
页数:11
相关论文
共 63 条
  • [31] Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer
    Nemunaitis, J
    Swisher, SG
    Timmons, T
    Connors, D
    Mack, M
    Doerksen, L
    Weill, D
    Wait, J
    Lawrence, DD
    Kemp, BL
    Fossella, F
    Glisson, BS
    Hong, WK
    Khuri, FR
    Kurie, JM
    Lee, JJ
    Lee, JS
    Nguyen, DM
    Nesbitt, JC
    Perez-Soler, R
    Pisters, KMW
    Putnam, JB
    Richli, WR
    Shin, DM
    Walsh, GL
    Merritt, J
    Roth, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (03) : 609 - 622
  • [32] NEMUNAITIS J, 2001, 37 ANN M AM SOC CL 1, V20, P255
  • [33] A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth
    Niethammer, AG
    Xiang, R
    Becker, JC
    Wodrich, H
    Pertl, U
    Karsten, G
    Eliceiri, BP
    Reisfeld, RA
    [J]. NATURE MEDICINE, 2002, 8 (12) : 1369 - 1375
  • [34] NIKITINA E, 2001, CLIN CANCER RES, V1, P2
  • [35] NOBEL TA, 1978, AM J PATHOL, V90, P783
  • [36] A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma
    O'Brien, MER
    Saini, A
    Smith, IE
    Webb, A
    Gregory, K
    Mendes, R
    Ryan, C
    Priest, K
    Bromelow, KV
    Palmer, RD
    Tuckwell, N
    Kennard, DA
    Souberbielle, BE
    [J]. BRITISH JOURNAL OF CANCER, 2000, 83 (07) : 853 - 857
  • [37] Angiostatin induces and sustains dormancy of human primary tumors in mice
    OReilly, MS
    Holmgren, L
    Chen, C
    Folkman, J
    [J]. NATURE MEDICINE, 1996, 2 (06) : 689 - 692
  • [38] Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
    OReilly, MS
    Boehm, T
    Shing, Y
    Fukai, N
    Vasios, G
    Lane, WS
    Flynn, E
    Birkhead, JR
    Olsen, BR
    Folkman, J
    [J]. CELL, 1997, 88 (02) : 277 - 285
  • [39] Palmer M, 2001, Clin Lung Cancer, V3, P49, DOI 10.3816/CLC.2001.n.018
  • [40] The role of the bystander effect in suicide gene therapy
    Pope, IM
    Poston, GJ
    Kinsella, AR
    [J]. EUROPEAN JOURNAL OF CANCER, 1997, 33 (07) : 1005 - 1016